Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 211

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 211
---
 |        2024 |       |   |     |         2023 |      |   |
| Net loss, as reported in the consolidated statements of comprehensive loss |     |             | 2,084 |   |     |             | 1,421 |   |     |              |  987 |   |
| Statutory tax rate                                                         |     |             |    21 | % |     |             |    23 | % |     |              |   23 | % |
| Computed “expected” tax income                                             |     |             |   437 |   |     |             |   326 |   |     |              |  227 |   |
| Valuation allowance                                                        |     |             |  (437 | ) |     |             |  (326 | ) |     |              | (227 | ) |
| Taxes on income                                                            |     |             |     - |   |     |             |     - |   |     |              |    - |   |

NOTE 10 – COMMITMENTS AND CONTINGENCIES

Predecessor:

The Predecessor’s
research is conducted at the Hebrew University (subject to license and research agreements) in Professor Bernholtz Yehezkel’s laboratory,
and the drug development activity is conducted through subcontractors.

The Predecessor
has signed an option agreement for an exclusive license for the technology with “Yissum Research Development Company of the Hebrew
University of Jerusalem Ltd.” (“Yissum”), the commercialization Company of the Hebrew University of Jerusalem.

In November
2022, the Predecessor exercised its option and signed a license agreement with Yissum.

Under the agreement,
the Predecessor undertook to finance research at Professor Bernholtz Yehezkel’s laboratory, promote the development of the products that
result from the research, and maintain the patents that result from the research.

The Predecessor
currently has three projects under four different agreements with Yissum:

LV-100 –
Liposomal Nano-Mupirocin: A new antibiotic treatment aimed at combating resistant bacteria which is in pre-clinical studies phase. The
Predecessor is obligated to pay royalties at the rate of 3% of net sales. The Predecessor shall pay Yissum the following amounts in connection
with the achievement of the following milestones per each Product (each, a “Milestone”): (1) $150 upon first patient enrolled
in a